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Abstract
Background: The goal of the present analysis was to investigate the long-term prognosis for
adenocarcinoma of the esophagus treated with either the transhiatal (TH) or the transthoracic
(TT) operative approach.
Methods: Between September 1985 and March 2004, esophageal resection due to carcinoma was
performed on a total of 424 patients. This manuscript takes into account the 150 patients suffering
from adenocarcinoma of the esophagus in whom a transhiatal resection of the esophagus was
performed. In the event of transmural tumor growth and a justifiable risk of surgery, the
transthoracic resection was selected. An extended mediastinal lymph node dissection, however,
was only carried out in the course of the transthoracic approach.
Results: The transthoracic resection of the esophagus demonstrated a higher rate of general
complications (p = 0.011) as well as a higher mortality rate (p = 0.011). The mediastinal dissection
of the lymph nodes, however, revealed no prognostic influence. Considering all of the 150 patients
with adenocarcinoma, as well as only those patients who had undergone curative resections (R0),
the transhiatal approach was seen to demonstrate a better five-year survival rate of 32.1% versus
35.1%, with a median survival time of 24 versus 28 months, as compared with those who had
undergone a transthoracic approach with a five-year survival rate of 13.6% (all patients) versus
17.7% (R0 resection) with a median survival time of 16 versus 17 months (p < 0.05).
Conclusion: The prognosis in patients with adenocarcinoma of the esophagus is influenced by the
depth of the tumor (pT) and the pM-category, as shown in the multivariate analysis. The present
analysis did not demonstrate a relevant difference in survival for patients with N0 and N1 stages
undergoing transhiatal or transthoracic esophagectomy. It is questionable, if a more extensive
mediastinal lymph node dissection, in addition to the clearance of abdominal lymph nodes, offers
prognostic advantages in adenocarcinoma of the esophagus. However, the morbidity and mortality
associated with the transthoracic approach is higher.
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The adequate operative procedure for adenocarcinoma of
the esophagus is currently being discussed with a great
deal of controversy. The question is whether or not the
prognosis can be improved through an extended lymph
node dissection by the transthoracic approach as com-
pared with the use of the transhiatal procedure combined
with removal of the posterior, lower mediastinal lymph
nodes. A randomized study comparing both operative
procedures revealed a higher morbidity following the
transthoracic approach, but no significant improvement
in the prognosis even when including tumors of the
esophagogastric junction [1]. Our own approach includes
the transhiatal resection as a routine procedure and dem-
onstrates a preference for the transthoracic approach in
the event of a suspected tumor infiltration of intrathoracic
or of an affliction of the mediastinal lymph nodes.
An analysis of 150 consecutive patients with adenocarci-
noma of the esophagus, who had undergone esophageal
resection and were evaluated prospectively, was carried
out in order to investigate the significance of the surgical
procedure on the prognosis.
Patients and methods
In 424 prospectively-evaluated patients, esophageal resec-
tions had been performed between September 1985 and
March 2004 due to the existence of malignant tumors. The
current data analysis, however, involves 150 patients with
histologically verified adenocarcinoma of the esophagus,
of whom 135 were Barrett's carcinoma. Adenocarcinoma
enrolled in this study only included Siewert type I tumors.
Type II (tumors of the cardia) and type III (subcardial
tumors with infiltration of the cardia) were strictly not
taken into consideration.
For preoperative staging, EUS (endoscopic ultrasound),
CT (computed tomography) of the neck, chest and abdo-
men and PET (positron emission tomography) were rou-
tinely carried out.
Aside from the selected surgical procedure, the following
parameters were documented:
The duration of surgery (incision-to-suture time), intraop-
erative blood loss as well as the intraoperative substitu-
tion of blood, time spent in the intensive care unit, tumor
staging according to the UICC classification [2], number
of tumor-free and tumor-infiltrated abdominal as well as
mediastinal lymph nodes, surgical complications (anasto-
motic insufficiency, transplant necrosis, postoperative
bleeding, tracheal fistula, recurrent laryngeal nerve paral-
ysis, chylothorax), general complications (pneumonia,
ARDS = adult respiratory distress syndrome, pulmonary
embolism, decompensated cardiac insufficiency, myocar-
dial infarction, transitional syndrome, renal insuffi-
ciency), duration of the postoperative hospital stay,
mortality (30-day and hospital mortality rate) as well as
the survival time have all been recorded. Until April 30,
2004, the end of the observation period for this study, the
long-term follow-up was recorded and evaluated. It was
possible to follow-up the post-stationary course of devel-
opment in each of these 150 patients.
For adenocarcinoma of the esophagus, a transhiatal resec-
tion of the esophagus was carried out as a routine proce-
dure. Patients with transmural tumor spread and
suspected intrathoracic lymph nodes involvement and a
justifiable risk of surgery, underwent a surgical procedure
employing the transthoracic approach. All together, 103
patients underwent transhiatal and 47 patients transtho-
racic resection. The transthoracic surgical approach was
performed via a right dorso-lateral thoracotomy, and the
esophageal substitute consisted of a gastric pull-up
located in the anatomical esophageal bed prevertebrally.
During transthoracic esophageal resection, the anastomo-
sis was usually done intrathoracically with a stapler (EEA
25 mm with an additional suture line by hand), whereas
patients undergoing the transhiatal procedure had a cervi-
cal, hand-sewn anastomosis (end-to-side esophagogas-
trostomy with two suture lines).
The transhiatal procedure was carried out with an abdom-
inal lymph node dissection (including the paracardial
nodes, the left gastric artery nodes along with the lymph
nodes of the lesser curvature of the stomach, the celiac
trunk, the common hepatic artery and in selected cases –
as macroscopic tumor involvement – the splenic artery),
as well as with an excision of the lymph nodes extending
as far as the carina of the trachea, and to those lymph
nodes which could be reached in the lower, posterior
mediastinum. The transthoracic technique involved an
abdominal (as described above) and a more extensive
mediastinal lymphadenectomy in the sense of a two-field
dissection. The specimen here included the lower and
middle mediastinal, subcarinal, and right-sided paratra-
cheal lymph nodes (en bloc dissection). Paratracheal and
bifurcal nodes were only removed on both sides in case of
clinical suspicion of bilateral involvement. The aortopul-
monary – window nodes were dissected separately. About
90% of the patients with adenocarcinomas (n = 133)
demonstrated a tumor localization in the distal third of
the esophagus.
Statistical analysis
In order to make a statistically-evaluative comparison
between the operative procedures, a minimum of two,
non-parametric statistical tests were applied to the meas-
ured parameters, making use of cross-tabulation analyses
(in association with Fisher's exact test), which werePage 2 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2005, 3:40 http://www.wjso.com/content/3/1/40employed for all categorized parameters involving (a)
parameters that are considered to be nominal variables or
(b) variables with a specific, ordinal scale value demon-
strating only two intensities or categories.
Additionally, the Mann-Whitney U test (M-W test or U-
test) was used for all of the parameters which could be
classified according to an ordinal scale and which also
demonstrated more than two intensities or categories.
Table 1: Clinicopathological features
Clinicopathological features
total transhiatal (TH) transthoracic (TT) p-value





61 (28–78) 63 (28–78) 60 (35–75) 0.199
U-test
ASA classification
ASA II 62 145 42.8% 44 99 44.4% 18 46 39.1% 0.592
ASA III-IV 83 145 57.2% 55 99 55.6% 28 46 60.9%
Fisher's exact test
R classification
RO 131 149 87.9% 94 102 92.2% 37 47 78.7% 0.029
R1, R2 18 149 12.1% 8 102 7.8% 10 47 21.3%
Fisher's exact test
tumor localization
upper third 1 149 0.7% 0 103 0.0% 1 46 2.2%
middle third 15 149 10.1% 8 103 7.8% 7 46 15.2% 0.155
lower third 133 149 89.3% 95 103 92.2% 38 46 82.6%
Chi-Square (Pearson)
pT category
pT1 28 150 18.7% 27 103 26.2% 1 47 2.1%
pT2 39 150 26.0% 34 103 33.0% 5 47 10.6% <0.0005
pT3 77 150 51.3% 41 103 39.8% 36 47 76.6%
pT4 6 150 4.0% 1 103 0.9% 5 47 10.6%
Chi-Square (Pearson)
pN category
pN0 51 146 34.9% 41 100 41.0% 10 46 21.7% 0.027
pN1-2 95 146 65.1% 59 100 59.0% 36 46 78.3%
Fisher's exact test
pM category
pM0 105 149 70.5% 75 102 73.5% 30 47 63.8% 0.250
pM1 44 149 29.5% 27 102 26.5% 17 47 36.2%
Fisher's exact test
UICC stage
UICC I-II 62 149 41.6% 53 102 52.0% 9 47 19.2% <0.0005
UICC III-IV 87 149 58.4% 49 102 48.0% 38 47 80.9%
Chi-Square (Pearson)
tumor grading
G1 10 146 6.9% 8 100 8.0% 2 46 4.4% 0.167
G2 43 146 29.5% 32 100 32.0% 11 46 23.9%
G3 76 146 52.1% 46 100 46.0% 30 46 65.2%
G4 17 146 11.6% 14 100 14.0% 3 46 6.5%
Chi-Square (Pearson)
tumor length (grouped)
0–4 cm 69 143 48.3% 52 98 53.1% 17 45 37.8% 0.225
>4–8 cm 62 143 43.4% 39 98 39.8% 23 45 51.1%
>8 cm 12 143 8.4% 7 98 7.1% 5 45 11.1%
Chi-Square (Pearson)Page 3 of 11
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formed in order to calculate the three-and five-year sur-
vival rate for subgroups, following either one of the two
surgical procedures. The median survival time, the specific
survival curves of the various random samples, were deter-
mined by Kaplan-Meier analyses (K-M analyses). Differ-
ences in survival between the groups were assessed with
the log-rank test. Multivariate survival analysis was per-
formed using the Cox proportional hazard model. As no
adjustment for multiple testing was performed, p-values
should be considered as descriptive.
Median, minimum and maximum values, as well as the
arithmetic mean and standard deviation, were also col-
lected for the descriptive statistics, accompanied by the
respective number of valid cases.
Results
With regard to age, ASA classification, tumor localization,
metastasis as well as tumor grading, there was no statisti-
cally significant difference between patients undergoing
the transhiatal or the transthoracic approach.
For those patients who had undergone transhiatal resec-
tions, individuals demonstrating both pT-category 1 and
2 were seen to be more frequent, compared to pT3-cate-
gory. These patients also had fewer lymph node metas-
tases (59% versus 78.3%, p = 0.027). Consequently, UICC
stages I and II were seen to be more prevalent in those
patients who had undergone transhiatal procedures (p <
0.0005) (Table 1). Tumor-free margins proximal, distal as
well as circumferential (R0 resections) were observed
more frequently following a transhiatal resection (92.2%)
as compared with those treated using a transthoracic
approach (78.7%) (p = 0.029) (Table 1).
Morbidity and mortality
The median time taken duration surgery for patients
undergoing transhiatal resection was 254 minutes as com-
pared with 335 minutes (without including the time
required to change the position of the patient) for those
undergoing a transthoracic resection (p < 0.0005).
The intraoperative blood loss was seen to be 800 ml
(under the transhiatal procedure) in contrast to 1000 ml
(using the transthoracic approach) (p = 0.002). The intra-
operative blood substitution was a median of 0 units of
packed red blood cells (PRBC) in the course of the transhi-
atal versus 1 unit during the transthoracic resection (p =
0.128) (Table 2).
The rate of surgical complications, with 42.7% (44/103)
for the transhiatal approach, was higher than that
observed in the course of a transthoracic resection
(14.9%) (7/47) (p = 0.001), primarily as a result of an
insufficiency of the cervical anastomosis, which could
Table 2: Morbidity and mortality
transhiatal (TH) transthoracic (TT) p-value
duration of surgery median (range) 254 (160–485) 335 (240–540) <0.0005
(min) U-test
blood loss median (range) 800 (0–7500) 1000 (200–5000) 0.002
(ml) intraoperatively U-test
blood substitution median (range) 0 (0–6) 1 (0–14) 0.128
(PRBC) intraoperatively U-test
surgical complications 44 103 42.7% 7 47 14.9% 0.001
Fisher
general complications 22 102 21.6% 20 47 42.6% 0.011
Fisher
total complications 62 103 60.2% 25 47 53.2% 0.477
Fisher
duration of postoperative intensive care unit stay
(days) median (range) 8 (2–107) 8 (1–97) 0.566
U-test
duration of postoperative in-hospital stay
(days) median (range) 21 (14–126) 20 (13–107) 0.646
hospital mortality 3 103 2.9% 7 47 14.9% 0.011
Fisher
30-day mortality 2 100 2.0% 7 47 14.9% 0.005
FisherPage 4 of 11
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of general complications, with 42.6% (20/47) versus
21.6% (22/102) (p = 0.011), was higher following the
transthoracic approach, which was associated with a
higher rate of pneumonia. The median duration spent in
the intensive care unit (8 days after both procedures; p =
0.566), as well as the median postoperative in-hospital
stay (21 versus 20 days; p = 0.646), did not differ between
the two types of resection (Table 2).
The hospital mortality for the entire population of
patients was seen to be 6.7% (10/150). Following the
transhiatal procedure, the 30-day (p = 0.005) and the hos-
pital mortality (p = 0.011) were lower than that observed
following the transthoracic approach (2.0 and 2.9% ver-
sus 14.9%) (Table 2). Causes of death were related to pul-
monary sepsis in one patient of the TT group only (the
others were due to cardiovascular problems (n = 5) and
anastomotic insufficiency with sepsis (n = 1)). Causes of
deaths following the TH-resection were pulmonary sepsis
(n = 1), hemorrhagic shock (n = 1) and acute rupture of
the mitral valve tendon (n = 1).
Lymph node status
The total number of lymph nodes dissected in the course
of transhiatal resection were lower (19; range 0–55) than
that observed during the transthoracic procedure (31,
range 2–94) (p < 0.0005) (Table 3). The number of
afflicted mediastinal lymph nodes dissected in the course
of transhiatal resection, correspondingly, was lower as
well (2 versus 4; p = 0.030). The lower number of excised
lymph nodes could be based on the lower number of
mediastinal lymph nodes which were seen to have been
removed in the course of the transhiatal approach (3 ver-
sus 9, p < 0.0005) (Table 3). Correspondingly, the
number of afflicted, mediastinal lymph nodes dissected
during transhiatal resection was lower (0 versus 2; p <
0.0005) (Table 3). The number of abdominal lymph
nodes which were excised was higher under the transhi-
atal in contrast to the transthoracic approach (14 versus
11, p = 0.017). The number of afflicted, abdominal lymph
nodes, however, revealed no difference between the two
operative procedures. The median lymph node-ratio
(quotient between the number of tumor-infiltrated lymph
nodes and the total number of lymph nodes dissected)
during transthoracic resection was seen to be 0.10 versus
0 for the transhiatal as compared with 0.154 versus 0.111
for the transthoracic procedure, respectively (p > 0.05)
(Table 3).
Prognosis
The median and the five-year survival rates for the total
patient population were markedly better following tran-
shiatal resection than subsequent to the transthoracic pro-
cedure (16 months and 32.1% as compared with 16
months and 13.6%, respectively; p = 0.018) (Table 4). For
patients with curative (R0) resection, the prognosis was
also seen to be better for those patients who underwent
transhiatal esophagectomy (28 months versus 17 months;
p = 0.045) (Figure 1). In patients without lymph node
Table 3: Lymph node (LN) dissection
transhiatal (TH) transthoracic (TT)
median range mean median range mean U-test
total LN 
dissected
19 (0–55) 21.3 31 (2–94) 32.4 <0.0005
positive LN 
dissected
2 (0–33) 5.4 4 (0–76) 7.9 0.030
total abdominal 
LN
14 (0–48) 16.4 11 (0–51) 12.0 0.017
positive 
abdominal LN
1 (0–28) 3.4 1 (0–17) 3.1 0.802
total thoracic 
LN
3 (0–42) 5.1 19 (2–83) 20.2 <0.0005
positive 
thoracic LN
0 (0–30) 1.5 2 (0–67) 4.8 <0.0005
LN ratio total 0.11 (0–0.86) 0.20 0.17 (0–0.81) 0.24 0.160
LK ratio 
abdominal
0.10 (0–0.89) 0.17 0.15 (0–1) 0.25 0.197
LK ratio 
thoracic
0.00 (0–1) 0.22 0.11 (0–1) 0.24 0.156Page 5 of 11
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R0 resection and a transhiatal approach was 67 months (n
= 40) as compared to 27 months for those who had
undergone transthoracic esophagectomy (n = 9) (p >
0.05). For the patients who were seen to be nodal-positive
(pN1), those who had undergone a transhiatal resection
(n = 51) demonstrated a median survival time of 16
months contrasted to 14 months for those treated using a
transthoracic approach (n = 26) (p > 0.05). An expansion
in the number of mediastinal lymph nodes which had
been dissected to include more than 19 lymph nodes
(=median), however, was not seen to have any positive
effect in this group (Table 4). In the scatter diagram (Fig-
ure 2), there was no correlation seen between the long-
term prognosis of adenocarcinomas of the esophagus and
the number of dissected mediastinal lymph nodes.
A relevant advantage to the transhiatal in comparison
with the transthoracic operative procedure (n = 32;
median survival time: 17 months; p = 0.044) was also to
be seen for tumor localizations in the distal third of the
esophagus (n = 86; median survival time: 30 months). For
the minority of patients with a tumor localization in the
middle third, however, there was no significant difference
between these two surgical approaches (TT : 4, TH : 8).
In the multivariate survival analysis, the simultaneous
influence of the surgical approach, R-classification, pT-,
pN-, pM-category, tumor grading, ASA classification, and
age was assessed. Only the pM-(p = 0.020) and pT-cate-
gory (p = 0.009) had a relevant influence on survival
(Table 5). In a forward variable selection pT and pM were
the only variables that were selected.
5-year survival rates for R0-resections according to the dif-
ferent UICC stages for the whole group were: stage I (n =
20): 56.3%; stage IIa (n = 20): 26.5%; stage IIb (n = 16):
16.5%; stage III (n = 34): 34.4%; and stage IV (n = 31):
14.8%. Multivariate analysis of three-and five-year sur-
vival including surgical approach and UICC staging
showed no significant influence of the surgical approach,
neither with respect to the three-nor to the five-year sur-
vival (3 years: p = 0.289; 5 years: p = 0.685) (Table 6, 7).
Table 4: Prognosis
operative approach n median survival 
(months)
5-year survival rate p-value
total TT 46 16 13.6% 0.018
TH 103 24 32.1%
curative (R0) TT 36 17 17.6% 0.045
TH 94 28 35.1%
palliative (R1) TT 10 9 - 0.778
TH 8 8 -
R0 pN0 TT 9 27 22.2% 0.072
TH 40 67 54.1%
R0 pN1 TT 26 14 14.3% 0.430 a
<19 thor. LN 12 17 16.7% 0.829 b
>/ = 19 thor. LN 14 8 -
TH 51 16 22,4% 0.703 c
R0 pN1 T1-2 TT 4 14 25.0% 0.357
TH 21 28 33.3%
R0 pN1 T3-4 TT 22 9 12.2% 0.793
TH 30 10 -
R0 pN1 ASA 1–2 TT 11 16 20.0% 0.345
TH 23 19 33.3%
R0pN1 ASA 3–4 TT 15 9 10.3% 0.999
TH 25 10 -
R0 middle third TT 4 5 25% 0.931
(tumor localization) TH 8 24 15%
R0 lower third TT 32 17 17.1% 0.044
(tumor localization) TH 86 30 37.9%
TT: Transthoracic, TH: Transhiatal
a = (TT vs. TH)
b= (TT intern)
c = (TT thor. LN vs. TH)Page 6 of 11
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The present investigation is based on 150 consecutive
patients who had undergone surgery for adenocarcinoma
of the esophagus and whose peri-and postoperative
course of was evaluated prospectively. The transhiatal
approach with the posterior excision of the lower medias-
tinal lymph nodes was employed as a routine procedure.
In the event that a tumor was to be found in the vicinity
of the tracheal bifurcation, or should there be suspicion of
an infiltration of intrathoracic organs or mediastinal
lymph node metastases, a transthoracic approach with
two-field lymphadenectomy was selected.
The study verified the varying perioperative risks of the
transthoracic and transhiatal procedures. With the same
age distribution and the same risk factors, measured
according to the ASA classification, the 30-day and hospi-
tal mortality following the transhiatal approach were seen
to be markedly reduced as compared with the
transthoracic procedure. This operative technique, how-
ever, primarily led to general complications, especially of
pulmonary kind, which served to bring about an unfavo-
rable course of development. The relatively high mortality
rate after the transthoracic procedure reflects patients seen
during the whole study period including the earlier inter-
val. Recently, probably due to improved surgical
techniques and advanced intensive care therapy, the rate
was seen to be much lower compared to the first study
period. Following transhiatal esophagectomy, the surgical
complications predominated, especially the insufficiency
of the cervical esophagogastrostomy, a condition which
was nevertheless seen to close in all cases subsequent to a
conservative therapy. The reduced general risk of the tran-
shiatal procedure has been confirmed in most of the avail-
able studies [3-6]. On the other hand, though exerting a
higher operative risk, transthoracic resection intends to
improve long-term survival by wide excision of the tumor
and peritumoral tissue with extended en bloc mediastinal
lymphadenectomy [7-11].
The influence of the operative procedure on the prognosis
in adenocarcinoma of the esophagus has been investi-
gated in a number of retrospective and in one prospective,
randomized study [1]. The disadvantage of the blunt tran-
shiatal resection is the reduced transthoracic lymph node
dissection, which is unfortunately limited to the lower
posterior, mediastinal lymph nodes [12-15]. In the
present investigation, a higher number of mediastinal
lymph nodes were consequently seen to be excised in the
course of transthoracic resections, a situation which has
also resulted in an increase in the number of involved
lymph nodes. The number of afflicted, abdominal lymph
nodes was seen to be similar following both of the two
types of operative procedures.
Our data show that through transhiatal esophagectomy, a
five-year survival rate of 54.1% was seen in patients with-
out (pN0) and of 22.4% in those with lymph node
involvement (pN1). Patients undergoing transthoracic
resection without afflicted lymph nodes demonstrated no
improvement in prognosis (22.2%) as a result of this pro-
cedure, although only a smaller number of such cases
were observed here. Findings derived from studies investi-
gating the spread of lymph nodes in cases of adenocarci-
noma allow one to conclude that the lymph node
metastases associated with distal adenocarcinomas are
initially seen to metastasize into the lymph nodes in the
vicinity of the tumor and only later into the lymph nodes
of the upper mediastinal region [16]. A counter argument
is a likelihood of cervical lymph node involvement as
high as 3.5% reported for T3 adenocarcinoma of the distal
esophagus and the gastro-esophageal junction [17]. Thus,
the transhiatal procedure must consequently be consid-
ered to be adequate at least for patients without any
lymph node involvement.
In cases with lymph node involvement, the prognosis of
our own patient population was independent of the sur-
gical procedure and, consequently, also of the extent of
lymph node dissection. The transhiatal esophagectomy,
because of the reduced morbidity and mortality and the
presence of more early stage tumors with correspondingly
more frequent R0 resections associated with this
Kaplan-Meier survival curves for patients with adenocarci-nom  and R0 resection undergoing ran hiatal (TH) and tran-sthoracic (TT) ophagectomyFigure 1
Kaplan-Meier survival curves for patients with adenocarci-
noma and R0 resection undergoing transhiatal (TH) and tran-
sthoracic (TT) esophagectomy.Page 7 of 11
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Correlation between long-term survival and the number of dissected thoracic lymph nodes (LN) for curative (R0) resected, 
nodal positive (pN1) patients (n = 77) with adenocarcinoma of the esophagus.































__ _ __ _ TT thor. LN < median
________ TT thor. LN >/= median
__ __ __ TH
>24 months survival (p=0.635; TT vs. TH)
TH 21.6 % (11/51)
TT < 19 thor. LN 27.3 % (3/11)
TT >/= 19 thor. LN 33.3 % (5/15)
survival (months)
correlation: r = -0.08 (p = 0.512)
thor.
LNPage 8 of 11
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term prognosis. Thus, the present study was not rand-
omized and the survival benefit seen after transhiatal
esophagectomy might therefore be based on a more favo-
rable patient selection. This needs to be checked in a ran-
domized controlled trial.
The higher number of advanced stages in the transthoracic
group is certainly explained by the marked difference in
Table 5: Multivariate analysis of prognostic factors for survival
95%-confidence interval
variable hazard ratio lower limit upper limit p-value
R-classification
-R1 and R2 vs. R0 1.368 0.772 0.2424 0.284
pT-category 0.009
-pT2 vs. pT1 2.418 0.952 6.144 0.063
-pT3 and pT4 vs. pT1 3.930 1.569 9.847 0.003
pN-category
-pN1, 2 vs. pN0 1.398 0.776 2.526 0.267
tumor grading 0.659
G2 vs. G1 0.731 0.264 2.021 0.545
G3 vs. G1 0.993 0.370 2.666 0.989
G4 vs. G1 1.082 0.348 3.360 0.892
ASA-classification 0.777
ASA III vs. ASA II 1.100 0.680 1.779 0.699
ASA IV vs. ASA II 1.391 0.544 3.558 0.491
pM-category 1.782 1.096 2.898 0.020
surgical approach
TT vs. TH 0.937 0.592 1.482 0.781
age 0.997 0.972 1.023 0.839
Table 6: Multivariate analysis of three-year survival
95%-confidence interval
variable odds ratio lower limit upper limit p-value
surgical approach
TT vs. TH 1.931 0.573 6.514 0.289
UICC 0.001
-IIa vs. I 1.866 0.459 7.583 0.383
-IIb vs. I 20.350 2.132 194.254 0.009
-III vs. I 5.967 1.400 25.439 0.016
-IV vs. I 46.422 5.071 424.994 0.001
Odds ratios are to be interpreted as odds for death so that they are interpretable in the same way as the hazard ratios in Table 5.Page 9 of 11
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migration due to the more extended lymph node dissec-
tion (pN-category: p = 0.027) (Table 1).
In the event of existing lymph node metastases, this indi-
cates that a generalized disease is present which can no
longer be influenced by local, surgical measures. In the
multivariate analysis of potential factors with an influence
on the long-term survival rate of our patient population,
the pT-and pM-category were seen to represent independ-
ent, prognostic parameters. In accordance with this, the
findings of other authors must also be expounded upon,
which demonstrated, following extensive lymph node
dissection in cases of adenocarcinoma, that the most favo-
rable results were to be observed in the event of lacking or
only minimal lymph node involvement [1].
The question of whether or not a neoadjuvant (radio-)
chemotherapy can lead to an improvement in the progno-
sis, as verified in one study, but not confirmed in another,
cannot presently be answered conclusively [18,19].
The prognosis following an R1 resection, subsequent to
both – transthoracic as well as transhiatal – approaches,
with survival times of 8 or 9 months, respectively, must be
considered unfavorable, so that this situation must be
avoided whenever possible.
For the operative procedure involving distal adenocarci-
nomas of the esophagus, the present results permit one to
make the following conclusions: The transhiatal proce-
dure together with a posterior, lower mediastinal lymph
node dissection is associated with a comparably reduced
perioperative risk and, for patients in whom a radical
tumor excision is possible, represents an oncologically
adequate method. The prognosis following R0 resection is
defined by the T-and N-categories. In the event of an N1
situation, the prognosis must be considered unfavorable,
independent of the operative procedure selected. Accord-
ing to the present investigation including a lack of rand-
omization, it is questionable, if the long-term survival can
be improved through the expansion of a lymph node dis-
section using the transthoracic procedure. This approach,
however, can then be indicated when a complete resection
of the tumor is not to be achieved by transhiatal
esophagectomy, for instance when the tumor is seen to
demonstrate a close relationship to the tracheal bifurca-
tion, the tumor is suspected to involve an infiltration of
intrathoracic structures or in the event of suspected lymph
node metastases in the upper mediastinal region.
Conclusion
The present analysis did not demonstrate a relevant differ-
ence in survival for patients with N0 and N1 stages under-
going transhiatal or transthoracic esophagectomy. It is
questionable, if an extensive mediastinal lymph node dis-
section in addition to the clearance of abdominal lymph
nodes offers any prognostic advantages in adenocarci-
noma of the esophagus also probably due to the increased
morbidity and mortality associated with the transthoracic
approach.
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